Educational Intervention on Oral Anticancer Agents for Community Pharmacists: Pilot RCT

June 24, 2026 updated by: Monash University Malaysia

Feasibility and Acceptability of an Educational Intervention on Oral Anticancer Agents for Community Pharmacists: a Pilot Randomized Controlled Trial

The overall aim of this study is to develop and test the feasibility and acceptability of an educational intervention for community pharmacists to help them support patients receiving OAAs in the community setting. This pilot randomized controlled trial aims to evaluate the feasibility, acceptability, and preliminary effect of an educational intervention on the knowledge and readiness in managing OAAs among community pharmacists in Malaysia.

PRIMARY OBJECTIVE • To evaluate the feasibility and acceptability of the educational intervention on OAAs among community pharmacists.

SECONDARY OBJECTIVE

• To obtain preliminary data on the effectiveness of the educational intervention to improve community pharmacists' knowledge and confidence in managing OAAs.

Participants will be randomly assigned to either the intervention group or control group in a 1:1 ratio using block randomization. After enrolling, participants will be asked to complete a baseline survey assessing their knowledge and confidence about managing OAAs. Immediately after completing the intervention, participants in the intervention group will repeat the same questionnaire to assess changes in their knowledge and confidence.

Results of this pilot study will inform the design of a larger study to definitively test whether this intervention improves community pharmacists' knowledge and readiness. This research may help better prepare community pharmacists to provide high-quality care to patients receiving OAAs.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND AND FRAMEWORK The educational intervention will be systematically developed using Intervention Mapping framework. The intervention will be designed to addresses identified gaps in knowledge and confidence among community pharmacists in managing OAAs, while also incorporating the needs and expectations of cancer patients to ensure patient-centred care.

INTERVENTION DEVELOPMENT The intervention will be co-designed through multidisciplinary collaboration with pharmacy educators, oncology clinical pharmacists, and community pharmacists. The intervention content will be validated by the expert panel, which included oncologist, oncology clinical pharmacists, and pharmacy educators. Stakeholder input will be obtained to refine the content, structure, and delivery of the intervention. Usability of the intervention will be evaluated during the development process, and feedback will be used to iteratively refine the educational materials and delivery format prior to implementation in the pilot trial.

CURRENT STUDY This pilot feasibility study represents MRC Phase 2 (feasibility and piloting) and follows CONSORT extension guidelines for pilot and feasibility trials.

STUDY DESIGN This is a randomized pilot feasibility study employing a mixed methods approach with parallel groups (intervention n=15, control n=15). The design compares community pharmacists receiving the educational intervention with pharmacists receiving no intervention.

INTERVENTION DESCRIPTION The intervention is an online educational program for community pharmacists focusing on the management of OAAs. The intervention will be developed through a co-design process involving the principal investigator, pharmacy educator, community pharmacist, and an experienced clinical pharmacist in oncology field, ensuring both pedagogical soundness and clinical authenticity. Developed using the Intervention Mapping framework, the program addresses identified knowledge and readiness gaps related to OAA adverse effect, drug interactions, and patient counselling. The intervention will be delivered through online lectures and interactive case-based workshops. Participants will engage in discussions and clinical scenarios designed to enhance their knowledge and confidence to provide care for patients receiving OAAs.

DATA COLLECTION Data collection occurs at three timepoints: baseline (T1), immediately post-intervention (T2), and 4 weeks post-intervention (T3). Quantitative measures include knowledge, readiness, and feasibility indicators. Qualitative data include semi-structured interviews with community pharmacists and educators.

ETHICAL CONSIDERATIONS All participants provide written informed consent after receiving comprehensive study information. Participation is voluntary with the right to withdraw at any time.

SIGNIFICANCE This pilot study will provide important information on the feasibility and acceptability of the educational intervention and inform the design and implementation of a future definitive randomized controlled trial. The findings will contribute to the evidence base on oncology education for community pharmacists and help address existing gaps in knowledge and confidence for managing OAAs in community pharmacy practice. Ultimately, this may support the provision of quality care for patients receiving OAAs in the community.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Malaysia
    • Selangor
      • Subang Jaya, Selangor, Malaysia
        • Monash University Malaysia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Currently a registered pharmacist working in community pharmacy in Malaysia
  • Provided written informed consent
  • Ability to read and understand English
  • Basic digital literacy and ability to use computer/tablet devices
  • Willingness to participate in all study procedures including surveys and potential interviews

Exclusion Criteria:

• Previous participation in educational intervention stakeholder evaluation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
Community pharmacists receive the educational intervention on oral anticancer agents.
Other: Educational intervention on managing oral anticancer agents in community pharmacy setting
Participants attend an educational program on managing oral anticancer agents in community pharmacy setting.
No Intervention: Control Group
Community pharmacists continue with usual practice only, without the educational intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility indicators composite
Time Frame: Baseline to 4-week follow up

Composite measure of five feasibility indicators:

  1. Recruitment: proportion of pharmacists who consent to participate in the study out of those who were approached and were eligible for participation. Time required to recruit target number of participants;
  2. Retention rate: proportion of participants who completed each outcome assessment at three measurement timepoints;
  3. Adherence rate: proportion of intervention group pharmacists who attended and completed the full educational program;
  4. Attrition rate: proportion of participants who dropped out of the study after enrolment among all participants. Reasons for dropout will also be recorded.
Baseline to 4-week follow up
Acceptability of the intervention
Time Frame: Immediately post-intervention
Acceptability of the intervention will be measured by a satisfaction questionnaire. Contents included participants' perceptions of the usefulness and satisfaction with the intervention.
Immediately post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knowledge of oral anticancer agents, confidence in managing oral anticancer agents
Time Frame: Baseline (T1), immediately post-intervention (T2), and 4 weeks post-intervention (T3)
Knowledge and confidence will be measured using a study questionnaire consisting of knowledge and confidence items regarding managing oral anticancer agents.
Baseline (T1), immediately post-intervention (T2), and 4 weeks post-intervention (T3)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Monash University Malaysia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

June 24, 2026

First Submitted That Met QC Criteria

June 24, 2026

First Posted (Actual)

June 30, 2026

Study Record Updates

Last Update Posted (Actual)

June 30, 2026

Last Update Submitted That Met QC Criteria

June 24, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • OAA-CP-PILOT-RCT-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Oral Anticancer Drugs

Clinical Trials on Educational intervention on managing oral anticancer agents in community pharmacy setting

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe